Additional Proxy Soliciting Materials (definitive) (defa14a)
January 21 2020 - 05:19PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
14A
Proxy
Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed
by the Registrant [X]
|
|
Filed
by a Party other than the Registrant [ ]
|
|
Check
the appropriate box:
|
[ ]
|
Preliminary
Proxy Statement
|
[ ]
|
Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
[ ]
|
Definitive
Proxy Statement
|
[X]
|
Definitive
Additional Materials
|
[ ]
|
Soliciting
Material under §240.14a-12
|
OncoSec
Medical Incorporated
|
(Name
of Registrant as Specified In Its Charter)
|
|
|
(Name
of Person(s) Filing Proxy Statement, if other than the Registrant)
|
Payment
of Filing Fee (Check the appropriate box):
|
[X]
|
No
fee required.
|
[ ]
|
Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
(1)
|
Title
of each class of securities to which transaction applies:
|
|
|
|
|
(2)
|
Aggregate
number of securities to which transaction applies:
|
|
|
|
|
(3)
|
Per
unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which
the filing fee is calculated and state how it was determined):
|
|
|
|
|
(4)
|
Proposed
maximum aggregate value of transaction:
|
|
|
|
|
(5)
|
Total
fee paid:
|
|
|
|
[ ]
|
Fee
paid previously with preliminary materials.
|
[ ]
|
Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date
of its filing.
|
|
(1)
|
Amount
Previously Paid:
|
|
|
|
|
(2)
|
Form,
Schedule or Registration Statement No.:
|
|
|
|
|
(3)
|
Filing
Party:
|
|
|
|
|
(4)
|
Date
Filed:
|
|
|
|
OncoSec
Announces the Appointment of Robert J. DelAversano, C.P.A, as Principal Accounting Officer and Controller
SAN
DIEGO & PENNINGTON, N.J., January 21, 2020 – OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company”
or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, announced today the appointment
of Robert J. DelAversano, C.P.A., as OncoSec’s Principal Accounting Officer and Controller, effective as of January 30,
2020. Mr. DelAversano will be responsible for preparation of financial statements, as well as other finance-related functions,
assuming these responsibilities from Sara M. Bonstein, who will be stepping down from her roles as Chief Financial Officer
and Chief Operating Officer to pursue another professional opportunity.
Mr.
DelAversano is a certified public account and has over fifteen years of experience in accounting including thirteen years in public
accounting. Prior to this appointment as OncoSec’s Principal Accounting Officer and Controller, Mr. DelAversano served as
OncoSec’s Executive Director of Finance since 2018 where he had global responsibility for accounting, external financial
reporting, and financial controls covering all aspects of OncoSec’s business. Prior to joining OncoSec, he was the Director
of Financial Reporting and Taxation at Brio Financial Group (“Brio”), where he served as the firm’s Director
of Financial Reporting and Taxation, consulting with various public companies in financial reporting, internal control development
and evaluation, budgeting and forecasting. Prior to joining Brio, Mr. DelAversano was a manager at Bartolomei Pucciarelli, LLC
and oversaw their accounting and tax practice with industry focuses in manufacturing, wholesalers and medical devices services.
In addition, he performed audit services, outsourced chief financial officer functions, and consulted clients through difficult
Securities and Exchange Commission comment periods particularly through application of complex accounting principles for a large
public company client base.
“Rob
is a highly trusted and respected member of the OncoSec team, and his experience and skill sets will ensure that the transition
is seamless,” said Daniel J. O’Connor, OncoSec’s President and Chief Executive Officer. “This is
an extremely exciting time for OncoSec. Pending approval from our shareholders and the completion of the strategic transaction
with China Grand Pharmaceutical and Healthcare Holdings Limited (“CGP”) and Sirtex Medical US Holdings, Inc. (“Sirtex”)
we are poised to unlock the value of TAVO™ and enter a new phase of evolution for the Company. We look forward to providing
additional updates in the near-term. We also want to thank Ms. Bonstein for her contributions to OncoSec and we wish her the best
moving forward in this next stage of her career.”
#
# #
About
OncoSec Medical Incorporated
OncoSec
Medical Incorporated (the “Company,” “OncoSec,” “we” or “our”) is a late-stage
biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body’s immune system
to target and attack cancer. OncoSec’s lead immunotherapy investigational product candidate – TAVO™ (tavokinogene
telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with
immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression
of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has
built a deep and diverse clinical pipeline utilizing TAVOTM as a potential treatment for multiple cancer indications
either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to
address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of
TAVOTM have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination
treatment approach. In addition to TAVOTM, OncoSec is identifying and developing new DNA-encoded therapeutic candidates
and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung
or pancreatic lesions. For more information, please visit www.oncosec.com.
TAVO™
trademark of OncoSec Medical Incorporated.
Risk
Factors and Forward Looking Statements
This
release, as well as other information provided from time to time by the Company or its employees, may contain forward-looking
statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated
in the forward-looking statements. Forward-looking statements provide the Company’s current beliefs, expectations and intentions
regarding future events and involve risks, uncertainties (some of which are beyond the Company’s control) and assumptions.
For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. You can identify forward-looking statements by the fact that they do not relate strictly to historical
or current facts. These statements may include words such as “anticipate,” “believe,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“should,” “will” and “would” and similar expressions (including the negative of these terms).
Although we believe that expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements. The Company intends these forward-looking statements to speak only at the time
they are published on or as otherwise specified, and does not undertake to update or revise these statements as more information
becomes available, except as required under federal securities laws and the rules and regulations of the Securities Exchange Commission
(“SEC”). In particular, you should be aware that the CGP/Sirtex Transaction may not close or may close on materially
different terms, that Alpha may succeed in obtaining the relief it seeks in its litigation against the Company, in whole or in
part, even though the Company believes that Alpha’s litigation is entirely without merit and that the success and timing
of our clinical trials, including safety and efficacy of our product candidates, patient accrual, unexpected or expected safety
events, and the usability of data generated from our trials may differ and may not meet our estimated timelines. Please refer
to the risk factors and other cautionary statements provided in the Company’s Annual Report on Form 10-K for the fiscal
year ended July 31, 2019 and subsequent periodic and current reports filed with the SEC (each of which can be found at the SEC’s
website www.sec.gov), as well as other factors described from time to time in the Company’s filings with the SEC.
Investor
/ Media Contacts:
Gem
Hopkins
Head
of Corporate Communications
858-210-7334
ghopkins@oncosec.com
or
Sloane
& Company
Dan
Zacchei / Joe Germani, 212-486-9500
dzacchei@sloanepr.com
/ jgermani@sloanepr.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Feb 2024 to Mar 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2023 to Mar 2024